Compare Fuso Pharmaceutical Industries Ltd. with Similar Stocks
Dashboard
1
Poor Management Efficiency with a low ROCE of 5.92%
- The company has been able to generate a Return on Capital Employed (avg) of 5.92% signifying low profitability per unit of total capital (equity and debt)
2
Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of 14.69
3
Poor long term growth as Net Sales has grown by an annual rate of 4.93% over the last 5 years
Stock DNA
Pharmaceuticals & Biotechnology
JPY 20,849 Million (Small Cap)
4.00
NA
0.00%
0.67
5.56%
0.59
Revenue and Profits:
Net Sales:
16,046 Million
(Quarterly Results - Jun 2026)
Net Profit:
642 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
8.47%
0%
8.47%
6 Months
-6.08%
0%
-6.08%
1 Year
2.8%
0%
2.8%
2 Years
-1.28%
0%
-1.28%
3 Years
10.94%
0%
10.94%
4 Years
13.87%
0%
13.87%
5 Years
-14.95%
0%
-14.95%
Fuso Pharmaceutical Industries Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
4.93%
EBIT Growth (5y)
3.83%
EBIT to Interest (avg)
13.90
Debt to EBITDA (avg)
2.18
Net Debt to Equity (avg)
0.45
Sales to Capital Employed (avg)
1.05
Tax Ratio
17.47%
Dividend Payout Ratio
38.21%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
5.63%
ROE (avg)
6.65%
Valuation key factors
Factor
Value
P/E Ratio
4
Industry P/E
Price to Book Value
0.56
EV to EBIT
14.73
EV to EBITDA
8.61
EV to Capital Employed
0.73
EV to Sales
0.68
PEG Ratio
0.05
Dividend Yield
NA
ROCE (Latest)
4.98%
ROE (Latest)
13.50%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Sideways
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'26 - YoY
Jun'26
Jun'25
Change(%)
Net Sales
16,046.00
15,503.00
3.50%
Operating Profit (PBDIT) excl Other Income
1,626.00
1,238.00
31.34%
Interest
104.00
70.00
48.57%
Exceptional Items
82.00
77.00
6.49%
Consolidate Net Profit
642.00
462.00
38.96%
Operating Profit Margin (Excl OI)
60.60%
38.50%
2.21%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2026 is 3.50% vs 6.03% in Jun 2025
Consolidated Net Profit
YoY Growth in quarter ended Jun 2026 is 38.96% vs -26.90% in Jun 2025
Annual Results Snapshot (Consolidated) - Mar'26
Mar'26
Mar'25
Change(%)
Net Sales
62,307.00
60,563.00
2.88%
Operating Profit (PBDIT) excl Other Income
5,258.00
5,958.00
-11.75%
Interest
328.00
161.00
103.73%
Exceptional Items
84.00
-8,660.00
100.97%
Consolidate Net Profit
2,011.00
-3,288.00
161.16%
Operating Profit Margin (Excl OI)
42.40%
68.20%
-2.58%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2026 is 2.88% vs 9.31% in Mar 2025
Consolidated Net Profit
YoY Growth in year ended Mar 2026 is 161.16% vs -338.78% in Mar 2025
About Fuso Pharmaceutical Industries Ltd. 
Fuso Pharmaceutical Industries Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available
Footer loading






